Please assess the completion status of the following clinical trial:

Trial Title: Safety and Pharmacokinetics of Dolutegravir in Pregnant HIV Mothers and Their Neonates: A Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Able to provide informed consent~* Willing to participate,~* Women age 18 years and above~* Pregnant~* Untreated HIV infection in late pregnancy at ≥28 - 36 weeks gestation~Exclusion Criteria:~* Received antiretroviral drugs in previous 6 months~* Ever received integrase inhibitors~* Serum haemoglobin \< 8.0 g/dl~* Elevations in serum levels of alanine aminotransferase (ALT) \>5 times the upper limit of normal (ULN) or ALT \>3xULN and bilirubin \>2xULN (with \>35% direct bilirubin)~* eGFR \< 50ml/min~* Active Hepatitis B infection, history or clinical suspicion of unstable liver disease, or subjects with severe liver disease (Class C by Childs-Hugh criteria)~* Severe pre-eclampsia (e.g. HELLP), or other pregnancy related events such as renal or liver abnormalities (e.g. grade 2 or above proteinuria, elevation in serum creatinine (above 2.5 x ULN), total bilirubin ALT or AST)~* Paternal non-consent (where disclosure to male partner has been made)~* Clinical depression or clinical judgement suggests increased risk of suicidality

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dolutegravir 50mg od (Type: EXPERIMENTAL): 30 patients who will receive dolutegravir 50mg once daily plus the same NRTI backbone as the active comparator group (lamivudine and tenofovir)
- Standard of Care (Type: ACTIVE_COMPARATOR): Patients randomised to receive antiretroviral therapy as per Uganda national guidelines (Efavirenz 600mg od based plus Tenofovir 300mg od and Lamivudine 300mg od)

Based on this trial design, predict the completion outcome and termination type (if applicable).